Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006

Derache, Anne; Maiga, A I; Traoré, Ousmane; Akonde, Alain; Cissé, Mamadou; Jarrousse, B; Koita, Victoria; Diarra, Bah; Carcelain, Guislaine; Barin, Françis; Pizzocolo, Cecilia; Pizarro, Louis; Katlama, Christine; Cálvez, Vincent; Marcelin, Anne–Geneviève

doi:10.1093/jac/dkn234

Cited by 41 publications

(39 citation statements)

References 26 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant difference between 2005 and 2006 in www.intechopen.com the prevalence of primary resistance of different classes of antiretroviral drugs has been observed. A similar study of treatment-naive patients recently showed a higher prevalence of primary resistance (9.9%) than was previously reported by Derache and colleagues Derache, 2008). So also have other studies reported late failures to drug treatment in Mali and in Burkina Faso with median treatment duration lasting 18 months (Sylla, 2008).…”

Section: Hiv Drug Resistance In Malisupporting

confidence: 63%

“…Currently 9 subtypes have been identified worldwide in the HIV-1 group M (A, B, C, D, F, G, H, J and K). Viruses E and I in the envelope are recombinant strains (Peeters, 1999 (Derache, 2008). A second recombinant strain was CRF06_cpx with 19.5% and 11% infections respectively occurring in the same period.…”

Section: Circulating Recombinants Forms Of Hiv In Malimentioning

confidence: 99%

“…These data demonstrates the need for the management of early failures to drug treatments and shows the importance of using other NRTIs in second-line treatments. Based on the 2007 version of an algorithm of interpretation by International AIDS Society (IAS) Derache and colleagues showed an overall prevalence for primary resistance of 11.5% (made up of 1.5% for NRTIs (K219Q), 9% to NNRTIs (Y181C, K101E, V90I, A98G and V106I and V108I) and 1% for PI (L33F and M46L)) (Derache, 2008). These identified mutations corresponded to the treatments used except for the mutations V90I, A98G and V106I which were associated with resistance to TMC 125 or Etravirine according to the IAS algorithm.…”

Section: Hiv Drug Resistance In Malimentioning

confidence: 99%

See 2 more Smart Citations

HIV Prevention Needs Epidemiological Data

Tounkara¹,

Koné²,

Diarra³

et al. 2011

HIV-infection - Impact, Awareness and Social Implications of Living With HIV/AIDS

View full text Add to dashboard Cite

Section: Hiv Drug Resistance In Malisupporting

confidence: 63%

Section: Circulating Recombinants Forms Of Hiv In Malimentioning

confidence: 99%

Section: Hiv Drug Resistance In Malimentioning

confidence: 99%

See 1 more Smart Citation

HIV Prevention Needs Epidemiological Data

Tounkara¹,

Koné²,

Diarra³

et al. 2011

HIV-infection - Impact, Awareness and Social Implications of Living With HIV/AIDS

View full text Add to dashboard Cite

“…Some studies have shown that these non-B subtypes may have natural polymorphisms described as ETR RAMs (5,14). Although ETR previously showed comparable activities against different group M subtypes (A to H), including several CRFs, the testing was done with few strains, and few data concerning the impact of the HIV-1 subtype on the virological response to ETR are currently available (1,24).…”

mentioning

confidence: 99%

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes

Maïga

Descamps

Morand‐Joubert

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Susceptibility to etravirine (ETR), an expanded-spectrum nonnucleoside reverse transcriptase inhibitor (NNRTI), is dependent on the type and number of NNRTI resistance-associated mutations (RAMs). Studies have shown that some HIV-1 subtypes may have natural polymorphisms described as ETR RAMs. This study addresses the prevalence of ETR RAMs in treatment-naïve patients infected with HIV-1 non-B subtypes and its potential impact on ETR susceptibility. The prevalence of ETR RAMs in 726 antiretroviral-naïve patients infected with non-B HIV-1 subtypes was studied. ETR genotypic resistance was interpreted according to Agence Nationale de Recherches sur le SIDA and Stanford algorithms. NNRTI phenotypic susceptibilities of samples with at least one ETR RAM were measured. Overall, 75 (10.3%) of 726 sequences harbored at least one ETR RAM: sequences from 72 patients (10%) each had one ETR RAM, and sequences from 3 patients (0.4%) each had two ETR RAMs (V90I and Y181C in one case and V90I and A98G in two cases). None of the viruses had three or more ETR RAMs, and none were consequently classified as resistant to ETR. All sequences with two ETR RAMs belonged to subtype CRF02_AG. The presence of one ETR RAM was statistically more frequent in subtype CRF02_AG than in other non-B subtypes (P ‫؍‬ 0.004). Three new mutation profiles (E138A and V179I, Y181C and H221Y, and V90I and Y181C) showing decreased ETR phenotypic susceptibility were identified. In conclusion, although the prevalence of ETR RAMs in treatment-naïve patients infected with non-B HIV-1 subtypes was 10%, in most cases this had no significant impact on ETR susceptibility. However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility.

show abstract

“…In this subtype, there is an intrinsic difficulty in synthesizing pol-A homopolymeric sequences that leads to template pausing at codon 65, facilitating the acquisition of K65R under selective drug pressure (Coutsinos et al, 2010;Coutsinos et al, 2009). The natural polymorphisms found in the RT of treatment-naive patients (10% in 726 patients) infected with HIV-1 non-B subtypes had no significant impact on susceptibility to ETR (Cotte et al, 2009;Derache et al, 2008;Maiga et al, 2010).…”

Section: Impact Of Hiv-1 Diversity In Drug Resistancementioning

confidence: 94%